Isofol Announces Recent Advisory Board Meeting Covering Development Plan for arfolitixorin

GOTHENBURG, Sweden, July 15, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the outcome of an advisory board meeting held to discuss the current status and ongoing strategy for the development of arfolitixorin, the company’s proprietary drug candidate being studied in the global pivotal Phase 3 AGENT study for advanced colorectal cancer. Arfolitixorin has the potential to significantly broaden and optimize the use of chemotherapy regimens containing fluorouracil (5-FU) for the treatment of metastatic colorectal cancer. The meeting, held during the 2019